TVTX
Travere Therapeutics, Inc.Company with tickers: TVTX
CIK
1438533
CUSIP
89422G107
Shares Outstanding
92,992,905
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $81,732,000 | USD | 2025-03-31 | 10-Q | 2026-05-04 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | — | ||||
| Operating Income | $-42,674,000 | USD | 2025-03-31 | 10-Q | 2026-05-04 |
| Net Income | $-41,226,000 | USD | 2025-03-31 | 10-Q | 2026-05-04 |
| EPS (Basic) | $-0.47 | USD/shares | 2025-03-31 | 10-Q | 2026-05-04 |
| EPS (Diluted) | $-0.47 | USD/shares | 2025-03-31 | 10-Q | 2026-05-04 |